Public Relations


"Starting with our proprietary positioning and messaging methodology – LHS Immersion® – we partner with clients to develop integrated communications’ programs that build influence and awareness and reach the right stakeholders, with the right messages at the right time."

--Sharon Correia

Our Public Relations services help our clients educate target audiences about their unique value proposition through corporate and product story development. We build influence and awareness to position our clients and/or their products as the right choice for critical stakeholders.
We provide:

Douglas Russell

Senior Vice President & General Manager

Phone: 617-374-8800 x108
Email: drussell@lavoiehealthscience.com

Sharon Correia

Senior Vice President, Integrated Communications

Phone: 617-374-8800 x105
Email: scorreia@lavoiehealthscience.com

Bell Ringer Merit Award 2016

PAIN: a conversation with highly-regarded speakers, digital content, advocacy group outreach, and media relations. The event drew a standing-room crowd, including several leaders and advocacy groups, to a premier Boston hotel for a networking reception and panel.

@LaVoieGroup

- 7 hours ago

RT @DDNewsOnline: Bioharmony & Boehringer Ingelheim to develop #bacteriophage lysins vs MDR Acinetobacter #infections Developed by Rockefe…
@LaVoieGroup

- 10 hours ago

We're excited to share news of a #collaboration between our client Bioharmony & @boehringerus. They will work to de… https://t.co/J7cWgTPDgW
@LaVoieGroup

- 12 hours ago

RT @bioharmonytrx: Pleased to share that Bioharmony has entered into a #collaboration with @boehringerus to develop bacteriophage lysins fo…
@LaVoieGroup

- 12 hours ago

Ranked as one of the top 30 independent #healthcare firms by Odwyer's PR, LaVoieHealthScience is dedicated to worki… https://t.co/0yiuxN01sv

Example of Public Relations: Panel Development

PAIN: a Conversation brought together industry leaders to participate in a discussion about opioid addition and the need for alternatives. This panel discussion drew nearly 100 clinicians, scientists, patient advocates, patients, investors and biotech/pharma industry professionals.